Achira
Achira builds molecular world models — foundation AI simulations blending geometric deep learning, generative AI, physics, and quantum chemistry — for pharmaceutical and biotech drug discovery partnerships. The company is pre-revenue and seed-funded.
- Company typePrivate
- Founded2024
- HeadquartersNew York, United States
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Achira does
Achira is a private deep-tech company founded in 2024 and headquartered in New York that builds molecular world models — foundation simulation models blending geometric deep learning, generative AI, physics, quantum chemistry, and statistical mechanics — to model matter at the atomistic scale. The company's stated thesis is that physical-law-grounded architecture converts intractable extrapolation in molecular property prediction into tractable interpolation, enabling higher data efficiency than pure-ML approaches and broader applicability than traditional molecular dynamics, which the company argues cannot exploit modern GPU compute. The intended applications are drug discovery and downstream materials design, framed as inverse-design problems.
Achira's product portfolio centers on a single core offering — Molecular World Models — with extension into agentic discovery through a June 2026 collaboration with NVIDIA. The team of approximately 15 named members spans machine learning, quantum chemistry, and engineering, supported by an advisory board drawn from Columbia, MIT, Stanford, and GV. The company has secured $33M in seed funding from Dimension, Amplify Partners, NVIDIA NVentures, and Compound.
The company's commercial model is a B2B enterprise partnership motion targeting pharmaceutical and biotech companies. Revenue streams are designed around subscription/recurring access to molecular world models and licensing or milestone-based collaboration fees; however, the company is pre-revenue, with first-generation models expected by late 2025 and no public pricing disclosed. Distribution relies on direct outreach to drug discovery scientists, academic advisory networks, and industry-conference presence rather than self-serve channels.
Achira firmographics
Firmographics- Name
- Achira
- Legal name
- Achira
- Website
- https://achira.ai/
- Company type
- Private
- Founded year
- 2024
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Achira builds molecular world models — foundation AI simulations blending geometric deep learning, generative AI, physics, and quantum chemistry — for pharmaceutical and biotech drug discovery partnerships. The company is pre-revenue and seed-funded.
- Ownership category
- akta.pro rank
Achira industry classification
Industry- Product category
- AI-Driven Drug Discovery / Computational Chemistry
- akta.pro primary industry
- AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)
- akta.pro secondary industry
- Cheminformatics & Molecular Modeling / CADD (HLAGAJAE)
Keywords
Where Achira is headquartered
LocationHeadquarters
- HQ city
- New York
- HQ country
- United States
- HQ region
- North America
Markets served
Achira business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Infrastructure, Operations
Revenue model
- Molecular World Model Access (B2B SaaS/Partnership): The company appears to generate revenue through partnerships with pharmaceutical and biotech companies, providing access to their molecular simulation models and AI-driven drug discovery platform. Given the early-stage nature and first-generation models expected by late 2025, the company is likely in a pre-commercial or partnership pilot phase.
- Drug Discovery Collaboration Fees: Revenue from collaborative drug discovery programs where Achira provides molecular modeling capabilities to pharmaceutical partners in exchange for research fees, milestone payments, or success-based compensation.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Achira product offering
Product offeringCore offering
Achira builds molecular world models—foundation simulation and generative models that blend geometric deep learning, generative AI, physics, quantum chemistry, and statistical mechanics—to model matter at the atomistic scale and accelerate drug discovery. The company partners with pharmaceutical and biotech firms to provide access to these models for biomolecular applications, transforming drug discovery into a tractable inverse design problem. First-generation models were expected by late 2025.
Product overview
Achira offers a unified platform of molecular world models designed to transform drug discovery and materials design. The core product consists of advanced foundation simulation models and generative models that blend geometric deep learning, generative AI, physics, quantum chemistry, and statistical mechanics. These models enable high-fidelity molecular simulation to improve drug discovery processes and enable inverse design of matter.
Differentiator
Problem solved
Functional benefit
Products and services
- Molecular World Models Foundation simulation and generative models that blend geometric deep learning, generative AI, physics, quantum chemistry, and statistical mechanics to model matter at the atomistic scale, enabling high-fidelity molecular simulation, generative molecule design, and inverse design of biomolecular structures for pharmaceutical and biotech customers.
Quantifiable outcome
- First-generation molecular simulation models expected by late 2025
Companies that use Achira
Customer profileSegments1 record
Ideal customer profiles1 record
Achira technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature5 records
Achira partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- NVIDIAcoreNVIDIA and Achira are collaborating to advance molecular world models for agentic discovery. This partnership leverages NVIDIA's computational infrastructure and AI capabilities to accelerate the development and deployment of Achira's molecular simulation platform. NVIDIA's VC arm NVentures is also a financial investor in the company.
Scale indicators4 records
Recent moves6 records
Expansion highlights5 records
Achira competitors and assessment
Company assessmentDirect peers
- Isomorphic Labs: Alphabet/DeepMind-founded AI drug discovery company building foundation models for molecular design. Directly comparable as an AI-first drug discovery platform pursuing physics-informed generative modeling for pharma partnerships.
- Insilico Medicine: Clinical-stage AI drug discovery company combining generative AI, physics-based methods, and traditional biology. Comparable to Achira as a competitor combining ML with physics/chemistry for end-to-end pharma discovery partnerships.
- Schrödinger, Inc. Public computational chemistry company combining physics-based molecular simulation with ML for drug discovery and materials design. Directly comparable as a platform provider selling physics-grounded molecular modeling to pharma and biotech.
- Recursion Pharmaceuticals: AI-driven drug discovery company combining high-throughput experimental data with ML foundation models. Comparable as a large-scale AI drug discovery platform pursuing a foundation model approach across biomolecular applications.
- Atomwise: AI drug discovery company using structure-based deep learning for small molecule design across pharma partnerships. Comparable as a direct competitor in AI-driven molecular discovery serving pharma customers.
- Genesis Therapeutics: AI-native drug discovery company combining geometric deep learning with physics-based simulation for molecular design. Highly comparable as a direct competitor pursuing a hybrid AI/physics foundation model approach for pharma partnerships.
- Iambic (formerly Entos): AI-driven molecular simulation company combining neural network potentials with quantum chemistry for drug discovery. Directly comparable as a competitor blending physics-based simulation with ML foundation models.
Emerging players
- Cradle Bio: Generative AI platform for protein engineering and molecule design targeting biotech and pharma customers. Comparable as a generative AI discovery platform, though focused more on biologics and protein design than small-molecule atomistic simulation.
- EvolutionaryScale: AI research lab building frontier models for biology and protein design, founded by former Meta AI researchers. Comparable as an emerging AI foundation model company targeting biomolecular applications, though earlier stage.
Broad incumbents
- DeepMind (AlphaFold): Google DeepMind division that produced AlphaFold for protein structure prediction and now drives Alphabet's Isomorphic Labs. Comparable as a broad incumbent in AI for biology whose protein-structure foundation models set the benchmark Achira is differentiating against.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Achira social profiles
Digital presenceAchira financial estimates
Financial estimateRevenue estimate
Valuation estimate
Achira leadership team
Management profileNumber of profiles
Profiles4 records
Achira funding detail
Funding detailFunding overview
Funding rounds1 record
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Achira M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Achira
What does Achira do?
Achira builds molecular world models—foundation simulation and generative models that blend geometric deep learning, generative AI, physics, quantum chemistry, and statistical mechanics—to model matter at the atomistic scale and accelerate drug discovery. The company partners with pharmaceutical and biotech firms to provide access to these models for biomolecular applications, transforming drug discovery into a tractable inverse design problem. First-generation models were expected by late 2025.
Is Achira a public or private company?
Achira is a private company. It is classified as venture growth investor backed and is currently operating.
When was Achira founded?
Achira was founded in 2024. It employs 11 to 50 people.
Where is Achira based?
Achira is headquartered in New York, United States, in the North America region.
How does Achira make money?
Two revenue lines are on record. Molecular World Model Access (B2B SaaS/Partnership) is the primary driver. The others are drug Discovery Collaboration Fees.
Who are Achira's main competitors?
Direct peers on record are Isomorphic Labs, Insilico Medicine, Schrödinger, Inc., Recursion Pharmaceuticals, Atomwise, Genesis Therapeutics and Iambic (formerly Entos). Emerging players are Cradle Bio and EvolutionaryScale. DeepMind (AlphaFold) is listed as a broad incumbent.
Does Achira have an API?
No public API is recorded for Achira.
What industry is Achira in?
Achira's product category is AI-Driven Drug Discovery / Computational Chemistry. Its primary akta.pro industry code is HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening), with a secondary code of HLAGAJAE, Cheminformatics & Molecular Modeling / CADD.